江西省初中女生免费接种二价人乳头瘤病毒疫苗安全性评价

赵红平; 刘莉红; 郑敏; 伍凤云; 郭世成; 刘杰

doi:10.16835/j.cnki.1000-9817.2024272

江西省初中女生免费接种二价人乳头瘤病毒疫苗安全性评价

doi: 10.16835/j.cnki.1000-9817.2024272

赵红平^{1, 2},
刘莉红³,
郑敏^{1, 2},
伍凤云^{1, 2, ,},
郭世成¹,
刘杰^{1, 2}

1.
江西省疾病预防控制中心免疫规划所, 南昌 330029
2.
江西省疾病预防控制中心青年科研创新攻关团队
3.
宜春市疾病预防控制中心免疫规划科

基金项目:

江西省卫生健康委科技计划项目 202211299

详细信息

作者简介:
赵红平(1987-)，男，湖北荆州人，硕士，主管医师，主要研究方向为疑似预防接种异常反应监测

通讯作者:
伍凤云, E-mail: 641880617@qq.com

利益冲突声明 所有作者声明无利益冲突。
中图分类号: R179 R186 G479
计量
- 文章访问数: 57
- HTML全文浏览量: 32
- PDF下载量: 10
- 被引次数: 0
出版历程
- 收稿日期: 2024-07-17
- 修回日期: 2024-08-21
- 网络出版日期: 2024-10-08
- 刊出日期: 2024-09-25

Safety evaluation of free bivalent human papilloma virus vaccine among junior middle school girls in Jiangxi Province

ZHAO Hongping^{1, 2},
LIU Lihong³,
ZHENG Min^{1, 2},
WU Fengyun^{1, 2
, ,},
GUO Shicheng¹,
LIU Jie^{1, 2}

1.
Department of Immunization Program, Jiangxi Provincial Center for Disease Control and Prevention, Nanchang (330029), Jiangxi Provinve, China

摘要

摘要: 目的评价江西省初中女生免费接种二价人乳头瘤病毒(HPV)疫苗的安全性，为HPV疫苗接种提供参考依据。方法通过江西省免疫规划信息系统收集2023年8月1日至2024年5月31日江西省初中女生二价HPV疫苗免费接种剂次数，并通过中国疾病预防控制信息系统疑似预防接种异常反应(AEFI)监测模块收集AEFI个案数据。采用描述性分析初中女生免费接种二价HPV疫苗后AEFI发生情况。结果江西省初中女生共免费接种二价HPV疫苗1 061 023剂次，报告AEFI 67例；其中一般反应50例，异常反应7例，心因性反应8例，偶合症2例。AEFI、不良反应和心因性反应报告率分别为6.31/10万、5.37/10万、0.75/10万；不良反应以一般反应为主(87.72%)，异常反应占12.28%。所有AEFI病例均治愈或好转，无死亡和伤残病例报告。结论江西省初中女生免费接种二价HPV疫苗安全性好，不良反应报告率低，且以一般反应为主，但应关注青少年心因性反应的预防。
- 乳头状瘤病毒疫苗 /
- 接种 /
- 学生 /
- 女(雌)性
Abstract: Objective To evaluate the safety of free bivalent human papilloma virus (HPV) vaccine for junior middle school girls in Jiangxi Province, so as to provide the reference for HPV vaccination. Methods The number of free inoculation of bivalent HPV vaccine for junior middle school girls in Jiangxi Province from August 1, 2023 to May 31, 2024 were collected by Jiangxi Provincial Immunization Planning Information System, and the cases of adverse events following immunization (AEFI) were collected by China Disease Prevention and Control Information System. A descriptive analysis was conducted to assess the incidence of AEFI among middle school girls who received free bivalent HPV vaccine. Results Junior middle school girls in Jiangxi Province were vaccinated with free bivalent HPV vaccine for 1 061 023 doses, and 67 cases of AEFI were reported. Among the 67 cases, there were 50 cases of general reaction, 7 cases of abnormal reaction, 8 cases of psychogenic reaction and 2 cases of coupling syndrome. The reported incidence of AEFI, adverse reactions and psychogenic reactions were 6.31/100 000, 5.37/100 000 and 0.75/100 000 respectively. Adverse reactions were primarily general reactions (87.72%), with abnormal reactions counting for 12.28%. All AEFI cases were cured or improved, and no death or disability cases were reported. Conclusion The free vaccination of bivalent HPV for junior high school girls in Jiangxi Province is identified as highly safe, low adverse reaction reporting rate, and mainly general reactions, but attention should be paid to the prevention of psychogenic reactions in adolescents.
- Papillomavirus vaccines /
- Vaccination /
- Students /
- Female
注释:

1) 利益冲突声明 所有作者声明无利益冲突。

HTML全文

表 1 江西省初中女生免费接种二价HPV疫苗后AEFI报告率

Table 1. AEFI reporting rates of junior middle school girls in Jiangxi Province after free vaccination with 2-HPV vaccine

剂次	接种剂次数	不良反应			心因性反应	偶合症	合计
剂次	接种剂次数	一般	异常	小计	心因性反应	偶合症	合计
1	661 364	36(5.44)	7(1.06)	43(6.50)	7(1.06)	2(0.30)	52(7.86)
2	399 659	14(3.50)	0	14(3.50)	1(0.25)	0	15(3.75)
合计	1 061 023	50(4.71)	7(0.66)	57(5.37)	8(0.75)	2(0.19)	67(6.31)
注：()内数字为报告率/10^-5。

下载: 导出CSV

表 2 江西省初中女生免费接种二价HPV疫苗后各月份AEFI报告率

Table 2. Reporting rates of AEFI among junior middle school girls in Jiangxi Province in different months after free vaccination with 2-HPV vaccine

接种时间	接种剂次数	不良反应			心因性反应	偶合症	合计
接种时间	接种剂次数	一般	异常	小计	心因性反应	偶合症	合计
2023年8月	238 074	16(6.72)	5(2.10)	21(8.82)	3(1.26)	1(0.42)	25(10.50)
2023年9月	174 531	6(3.44)	2(1.15)	8(4.58)	3(1.72)	1(0.57)	12(6.88)
2023年10月	63 113	4(6.34)	0	4(6.34)	0	0	4(6.34)
2023年11月	7 933	0	0	0	0	0	0
2023年12月	3 418	1(29.26)	0	1(29.26)	0	0	1(29.26)
2024年1月	693	0	0	0	0	0	0
2024年2月	64 855	1(1.54)	0	1(1.54)	0	0	1(1.54)
2024年3月	227 843	8(3.51)	0	8(3.51)	1(0.44)	0	9(3.95)
2024年4月	155 642	4(2.57)	0	4(2.57)	0	0	4(2.57)
2024年5月	124 921	10(8.01)	0	10(8.01)	1(0.80)	0	11(8.81)
注：()内数字为报告率/10^-5。

下载: 导出CSV

参考文献(17)

[1]	王慧芳, 陈鲤, 丘东海, 等. 宫颈上皮内瘤变合并高危型人乳头瘤病毒感染的临床特征[J]. 微创医学, 2024, 19(2): 139-143. WANG H F, CHEN L, QIU D H, et al. Clinical features of cervical intraepithelial neoplasia combined with high risk human papilloma virus infection[J]. J Minim Invasive Med, 2024, 19(2): 139-143. (in Chinese)
[2]	穆仪冰, 吴颖岚, 陈霞. 人乳头瘤病毒疫苗接种不良反应及相关因素分析[J]. 中国药物警戒, 2020, 17(4): 221-226. MU Y B, WU Y L, CHEN X. Analysis of adverse drug reactions induced by human papillomavirus vaccination[J]. Chin J Pharmacovigil, 2020, 17(4): 221-226. (in Chinese)
[3]	吴春花. 二价人乳头瘤病毒疫苗接种后不良反应发生原因及相关处理措施分析[J]. 基层医学论坛, 2023, 27(26): 129-131. WU C H. Analysis on the causes of adverse reactions after bivalent human papillomavirus vaccination and related treatment measures[J]. Med Forum, 2023, 27(26): 129-131. (in Chinese)
[4]	KAUR G, CASEY R M, PATEL J C, et al. Status of new vaccine introduction-worldwide, 2016-2021[J]. Morb Mortal Wkly Rep, 2023, 72(27): 746-750. doi: 10.15585/mmwr.mm7227a2
[5]	江西省卫生健康委员会. 关于印发《江西省加速消除宫颈癌行动计划(2023—2030年)工作方案》的通知[EB/OL]. (2023-07-11)[2024-07-13]. http://hc.jiangxi.gov.cn/art/2023/7/11/art_38168_4529175.html. Health Commission of Jiangxi Province. Notice on issuing the Work Plan of the Action Plan for Accelerating the Elimination of Cervical Cancer in Jiangxi Province (2023-2030)[EB/OL]. (2023-07-11)[2024-07-13]. http://hc.jiangxi.gov.cn/art/2023/7/11/art_38168_4529175.html.(in Chinese)
[6]	国家疾病预防控制局综合司, 中华人民共和国国家卫生健康委办公厅关于印发预防接种工作规范(2023年版)的通知[EB/OL]. (2023-11-30)[2024-07-13]. https://www.gov.cn/zhengce/zhengceku/202312/content_6920274.htm. Comprehensive Department of National Disease Control and Prevention Administration, General Office of National Health Commission of the PRC notice on issuing the regulations for preventive vaccination work (2023 edition)[EB/OL]. (2023-11-30)[2024-07-13]. https://www.gov.cn/zhengce/zhengceku/202312/content_6920274.htm. (in Chinese)
[7]	中华人民共和国卫生部办公厅, 国家食品药品监督管理局办公室关于印发《全国疑似预防接种异常反应监测方案》的通知[EB/OL]. (2010-06-03)[2024-07-13]. https://www.nmpa.gov.cn/xxgk/fgwj/qita/20100603120001618.html. General Office of the Ministry of Health of the PRC and the Office of the State Food and Drug Administration notice on issuing the National Monitoring Program for Suspected Abnormal Reaction of Vaccination[EB/OL]. (2010-06-03)[2024-07-13]. https://www.nmpa.gov.cn/xxgk/fgwj/qita/20100603120001618.html. (in Chinese)
[8]	谭洁冰, 钟晓玮, 班靖洋, 等. 9~45岁女性接种一款重组二价人乳头瘤病毒疫苗安全性和免疫原性的开放性Ⅰ期临床试验[J]. 中国疫苗和免疫, 2023, 29(1): 58-63. TAN J B, ZHONG X W, BAN J Y, et al. Safety and immunogenicity of a recombinant bivalent human papillomavirus vaccine among females 9-45 years of age: a phase Ⅰ, open label clinical trial[J]. Chin J Vaccin Immun, 2023, 29(1): 58-63. (in Chinese)
[9]	张丽娜, 李克莉, 李燕, 等. 2020年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2022, 28(2): 208-218. ZHANG L N, LI K L, LI Y, et al. Surveillance of adverse events following immunization in China, 2020[J]. Chin J Vaccin Immun, 2022, 28(2): 208-218. (in Chinese)
[10]	张丽娜, 李克莉, 李燕, 等. 2017—2020年中国人乳头瘤病毒疫苗疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2023, 29(4): 451-457. ZHANG L N, LI K L, LI Y, et al. Surveillance for adverse events following immunization with human papillomavirus vaccines in China, 2017-2020[J]. Chin J Vaccin Immun, 2023, 29(4): 451-457. (in Chinese)
[11]	周开举, 赵占杰, 梁文佳, 等. 2018—2020年广东省人乳头瘤病毒疫苗疑似预防接种异常反应监测分析[J]. 华南预防医学, 2022, 48(6): 707-710. ZHOU K J, ZHAO Z J, LIANG W J, et al. Monitoring and analysis of abnormal reaction of suspected vaccination of human papillomavirus vaccine in Guangdong Province from 2018 to 2020[J]. South China J Prev Med, 2022, 48(6): 707-710. (in Chinese)
[12]	黄荣东, 张冬娟, 萧剑雄. 福建省2020年人乳头瘤病毒疫苗疑似预防接种异常反应监测[J]. 海峡预防医学杂志, 2021, 27(5): 10-12. HUANG R D, ZHANG D J, XIAO J X. Monitoring of abnormal reaction of suspected vaccination of human papillomavirus vaccine in Fujian Province in 2020[J]. Strait J Prev Med, 2021, 27(5): 10-12. (in Chinese)
[13]	刘捷宸, 吴琳琳, 白庆瑞, 等. 上海市2017—2019年人乳头瘤病毒疫苗接种率和疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2020, 26(3): 322-325, 348. LIU J C, WU L L, BAI Q R, et al. Surveillance for coverage of human papilloma virus (HPV) vaccine and adverse events following immunization with HPV vaccine in Shanghai, 2017-2019[J]. Chin J Vaccin Immun, 2020, 26(3): 322-325, 348. (in Chinese)
[14]	孙肖瑜, 魏晶娇, 郑晓春, 等. 2018—2019年温州市女性人乳头瘤病毒疫苗疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2020, 26(4): 376-378, 382. SUN X Y, WEI J J, ZHENG X C, et al. Surveillance of adverse events following immunization with human papillomavirus vaccine among females in Wenzhou City, 2018-2019[J]. Chin J Vaccin Immun, 2020, 26(4): 376-378, 382. (in Chinese)
[15]	范张洁, 李锋, 许海燕, 等. 2019—2022年郑州市人乳头瘤病毒疫苗疑似预防接种异常反应监测结果[J]. 现代疾病预防控制, 2024, 35(4): 313-317. FAN Z J, LI F, XU H Y, et al. Monitoring results of adverse events following immunization of human papillomavirus vaccine in Zhengzhou City from 2019 to 2022[J]. Mod Dis Control Prev, 2024, 35(4): 313-317. (in Chinese)
[16]	潘佑记, 许雷, 张嘉陵, 等. 2019—2022年连云港市人乳头瘤病毒疫苗接种率和疑似预防接种异常反应监测分析[J]. 江苏预防医学, 2024, 35(2): 205-208. PAN Y J, XU L, ZHANG J L, et al. Coverage of human papillomavirus vaccination and surveillance of suspected adverse events following immunization in Lianyungang City during 2019-2022[J]. Jiangsu J Prev Med, 2024, 35(2): 205-208. (in Chinese)
[17]	郑敏, 伍凤云, 赵红平, 等. 江西省2017—2022年人乳头瘤病毒疫苗疑似预防接种异常反应监测分析[J]. 现代预防医学, 2024, 51(4): 748-751, 758. ZHENG M, WU F Y, ZHAO H P, et al. Surveillance of adverse events following immunization with human papilloma virus vaccine in Jiangxi, 2017-2022[J]. Mod Prev Med, 2024, 51(4): 748-751, 758. (in Chinese)